Effect of CPU-XT-008, a combretastatin A-4 analogue, on the proliferation, apoptosis and expression of vascular endothelial growth factor and basic fibroblast growth factor in human umbilical vein endothelial cells

Xiong,Rui; Sun,Jing; Liu,Kun; Xu,Yungen; He,Shuying

doi:10.3892/ol.2015.3867

Effect of CPU-XT-008, a combretastatin A-4 analogue, on the proliferation, apoptosis and expression of vascular endothelial growth factor and basic fibroblast growth factor in human umbilical vein endothelial cells

Authors:
- Rui Xiong
- Jing Sun
- Kun Liu
- Yungen Xu
- Shuying He
View Affiliations

Affiliations: School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu 211198, P.R. China, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China
Published online on: November 5, 2015 https://doi.org/10.3892/ol.2015.3867
Pages: 491-499

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the effect of the combretastatin A-4 analogue CPU-XT‑008 on the proliferation, apoptosis and expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF‑2) in human umbilical vein endothelial cells (HUVECs). The proliferation capacity of HUVECs was analyzed with a cell viability assay, while their apoptosis and migration abilities were evaluated via flow cytometry and monolayer denudation assay, respectively. The mRNA and protein expression levels of VEGF and FGF‑2 in these cells were determined by reverse transcription-polymerase chain reaction, and cell‑based ELISA, western blotting and immunocytochemistry, respectively. The results demonstrated that CPU‑XT‑008 inhibited proliferation and migration, and induced apoptosis in HUVECs in a dose‑dependent manner. In addition, CPU‑XT‑008 downregulated the mRNA and protein expression levels of VEGF and FGF‑2 in these cells. These findings suggest that CPU‑XT‑008 exerts anti-angiogenic effects in HUVECs, which may explain the inhibition of cell proliferation and migration, induction of apoptosis, and reduction in the mRNA and protein expression levels of VEGF and FGF-2 observed in the present study.

View Figures

View References

1	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
2	Roodink I and Leenders WP: Targeted therapies of cancer: Angiogenesis inhibition seems not enough. Cancer Lett. 299:1–10. 2010. View Article : Google Scholar : PubMed/NCBI
3	Park HE, Baek SH, Min J, Chang YT, Kang DK, Chang SI and Joe YA: Myoseverin is a potential angiogenesis inhibitor by inhibiting endothelial cell function and endothelial progenitor cell differentiation. DNA Cell Biol. 25:514–522. 2006. View Article : Google Scholar : PubMed/NCBI
4	Kretzschmann VK and Furst R: Plant-derived vascular disrupting agents: Compounds, actions, and clinical trials. Phytochem Rev. 13:191–206. 2014. View Article : Google Scholar
5	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
6	Van Beijnum JR, Dings RP, van der Linden E, Zwaans BMM, Ramaekers FCS, Mayo KH and Griffioen AW: Gene expression of tumor angiogenesis dissected: Specific targeting of colon cancer angiogenic vasculature. Blood. 108:2339–2348. 2006. View Article : Google Scholar : PubMed/NCBI
7	Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R and Bani MR: Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics. 9:2012008. View Article : Google Scholar : PubMed/NCBI
8	Torijano-Gutiérrez S, Díaz-Oltra S, Falomir E, Murga J, Carda M and Marco JA: Synthesis of combretastatin A-4 O-alkyl derivatives and evaluation of their cytotoxic, antiangiogenic and antitelomerase activity. Bioorg Med Chem. 21:7263–7274. 2013.
9	Cross MJ and Claesson-Welsh L: FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 22:201–207. 2001. View Article : Google Scholar : PubMed/NCBI
10	Casanovas O, Hicklin DJ, Bergers G and Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 8:299–309. 2005. View Article : Google Scholar : PubMed/NCBI
11	Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP and Schwartz SA: Gene expression of angiogenic factor correlates with metastatic potential of prostate cancer cells. Cancer Res. 64:5311–5321. 2004. View Article : Google Scholar : PubMed/NCBI
12	Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS and Garcia-Kendall D: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 45:209–211. 1989. View Article : Google Scholar : PubMed/NCBI
13	Krilleke D, DeErkenez A, Schubert W, Giri I, Robinson GS, Ng YS and Shima DT: Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. J Biol Chem. 282:28045–28056. 2007. View Article : Google Scholar : PubMed/NCBI
14	Parihar S, Kumar A, Chaturvedi AK, Sachan NK, Luqman S, Changkija B, Manohar M, Prakash O, Chanda D, Khan F, et al: Synthesis of combretastatin A4 analogues on steroidal framework and their anti-breast cancer activity. J Steroid Biochem Mol Biol. 137:332–344. 2013. View Article : Google Scholar : PubMed/NCBI
15	Böhle AS, Leuschner I, Kalthoff H and Henne-Bruns D: Combretastatin A-4 prodrug: A potent inhibitor of malignant hemangioendothelioma cell proliferation. Int J Cancer. 87:838–843. 2000. View Article : Google Scholar : PubMed/NCBI
16	Petit I, Karajannis MA, Vincent L, Young L, Butler J, Hooper AT, Shido K, Steller H, Chaplin DJ, Feldman E and Rafii S: The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood. 111:1951–1961. 2008. View Article : Google Scholar : PubMed/NCBI
17	Kremmidiotis G, Leske AF, Lavranos TC, Beaumont D, Gasic J, Hall A, OCallaghan M, Matthews CA and Flynn B: BNC105: A novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther. 9:1562–1573. 2010. View Article : Google Scholar : PubMed/NCBI
18	Khachigian LM and Parish CR: Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev. 22:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
19	Norrby K: Low-molecular-weight heparins and angiogenesis. APMIS. 114:79–102. 2006. View Article : Google Scholar : PubMed/NCBI
20	Bussolati B, Deregibus MC and Camussi G: Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. Curr Vasc Pharmacol. 8:220–232. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhou J, Jin J, Zhang Y, Yin Y, Chen X and Xu B: Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4. Eur J Med Chem. 68:222–232. 2013. View Article : Google Scholar : PubMed/NCBI
22	Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1829–1834. 1997.PubMed/NCBI
23	Magalhães HI, Wilke DV, Bezerra DP, Cavalcanti BC, Rotta R, de Lima DP, Beatriz A, Moraes MO, Diniz-Filho J and Pessoa C: (4-Methoxyphenyl)(3,4,5-trimethoxyphenyl) methanone inhibits tubulin polymerization, induces G₂/M arrest, and triggers apoptosis in human leukemia HL-60 cells. Toxicol Appl Pharmacol. 272:117–126. 2013. View Article : Google Scholar : PubMed/NCBI
24	Nathwani SM, Hughes L, Greene LM, Carr M, OBoyle NM, McDonnell S, Meegan MJ and Zisterer DM: Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro. Oncol Rep. 29:585–594. 2013.PubMed/NCBI
25	Nör JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM and Polverini PJ: Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 61:2183–2188. 2001.PubMed/NCBI
26	Tran J, Master Z, Yu JL, Rak J, Dumont DJ and Kerbel RS: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci. 99:4349–4354. 2002. View Article : Google Scholar : PubMed/NCBI
27	Xu CJ, Mikami T, Nakamura T, Tsuruta T, Nakada N, Yanagisawa N, Jiang SX and Okayasu I: Tumor budding, myofibroblast proliferation and fibrosis in obstructing colon carcinoma: The roles of Hsp47 and basic fibroblast growth factor. Pathol Res Pract. 209:69–74. 2013. View Article : Google Scholar : PubMed/NCBI
28	Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE and Fortier AH: Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine. 19:1294–1303. 2001. View Article : Google Scholar